Zdzislaw Szulc to Acid Ceramidase
This is a "connection" page, showing publications Zdzislaw Szulc has written about Acid Ceramidase.
Connection Strength
0.930
-
Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer. Cells. 2020 12 15; 9(12).
Score: 0.166
-
Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020 11; 135:155219.
Score: 0.161
-
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase. PLoS One. 2017; 12(6):e0177805.
Score: 0.130
-
Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine. Int J Cancer. 2016 09 15; 139(6):1372-8.
Score: 0.121
-
Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15; 22(24):6933-44.
Score: 0.108
-
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 2011 Apr 15; 71(8):2882-91.
Score: 0.085
-
Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem. 2009 Mar 01; 17(5):1840-8.
Score: 0.073
-
Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats. Behav Brain Res. 2009 Jan 30; 197(1):41-4.
Score: 0.070
-
Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes. J Invest Dermatol. 2008 Feb; 128(2):389-97.
Score: 0.016